Open AccessUSE OF CHLOROQUINE IN ASYMPTOMATIC ELDERLY COVID19 PATIENTS, A PLACEBO OR RATHER A SOURCE OF COMPLICATIONS: A CASE REPORT
Author(s) -
Ilham Benyamna
Publication year - 2021
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/12673
Subject(s) - asymptomatic , medicine , chloroquine , placebo , azithromycin , cohort , disease , venous thrombosis , hydroxychloroquine , thrombosis , pandemic , pediatrics , intensive care medicine , surgery , covid-19 , immunology , pathology , antibiotics , infectious disease (medical specialty) , alternative medicine , malaria , microbiology and biotechnology , biology
Coronavirus 19 is a virus that caused a pandemic that started in Wuhan, CHINA in December 2019. Whatever it is a respiratory tropism virus, it can cause thromboembolic complications. The disease seems to be more severe in older patients with this virus. However, the introduction of treatment for this purpose remains to be discussed in asymptomatic older subjects. We report the case of a 90-year-old man positive for covid 19 but totally asymptomatic on admission. The administration of chloroquine combined with azithromycin caused digestive side effects leading to dehydration, probably resulting in cerebral venous thrombosis on the 5th day of treatment. The review of the literature and in the absence of large cohort studies demonstrating the value of these treatments, leads us to propose treatment on a case-by-case basis and even better to avoid it in asymptomatic elderly subjects without comorbidities.